Septerna, Inc. (SEPN)
| Market Cap | 1.08B |
| Revenue (ttm) | 981,000 |
| Net Income (ttm) | -19.85M |
| Shares Out | 44.40M |
| EPS (ttm) | -8.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,911,476 |
| Open | 23.40 |
| Previous Close | 23.40 |
| Day's Range | 20.61 - 24.69 |
| 52-Week Range | 18.62 - 27.47 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 43.67 (+79.86%) |
| Earnings Date | Feb 15, 2025 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves’ disease and thyroid eye disease. It also develops o... [Read more]
Analyst Forecast
According to 4 analysts, the average rating for SEPN stock is "Strong Buy." The 12-month stock price forecast is $43.67, which is an increase of 79.86% from the latest price.
News
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer...
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones
A couple of analysts initiated coverage on Septerna, Inc. SEPN, which debuted on NASDAQ last month.
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral smal...
U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names
Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies - Ingram Micro, Septerna, and WeRide. Several small issuers also listed this past week, includin...
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut
Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.
Septerna Prices Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral smal...
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO
Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.
Biotech Septerna aims to raise up to $186 million in US IPO
Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline
Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment market i...
Septerna IPO Registration Document (S-1)
Septerna has filed to go public with an IPO on the NASDAQ.